Michael McCartney, MD
Internal Medicine · Newburyport, MANPI 1245211903
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,139 and has fallen 94.7% since, to $114 in 2024. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 148 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$598
- Pfizer$413
- AstraZeneca$345
- Johnson & Johnson$328
- Novo Nordisk$211
- Amgen$183
- plus $1K from 19 others
Across 623 payments — averaging $28,225 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$8.4M
- Pfizer$3M
- Eli Lilly$2.6M
- Biogen$1.3M
- Bavarian Nordic A/s$884K
- Modernatx, Inc.$557K
- plus $924K from 17 others
What the payments were for
- Food & beverage$3,27499%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 26 | $598 |
| Pfizer | 19 | $413 |
| AstraZeneca | 9 | $345 |
| Johnson & Johnson | 11 | $328 |
| Novo Nordisk | 8 | $211 |
| Amgen | 10 | $183 |
| GSK | 9 | $147 |
| Amarin Pharma, Inc. | 6 | $129 |
| Astellas Pharma US Inc | 6 | $121 |
| E.r. Squibb & Sons, L.L.C. | 6 | $114 |
| Boehringer Ingelheim | 5 | $109 |
| Merck | 5 | $99 |
| Sanofi-aventis U.S. LLC | 5 | $91 |
| Biogen | 3 | $78 |
| Biohaven Pharmaceuticals, Inc. | 2 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Shire North American Group Inc | 2 | $37 |
| Abbott | 2 | $35 |
| Genentech USA, Inc. | 2 | $29 |
| AbbVie | 2 | $23 |
| Bardy Diagnostics, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,297 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 121 | $112,675 |
| MounjaroTirzepatide | 63 | $61,767 |
| JardianceEmpagliflozin | 28 | $34,449 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $24,460 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $23,978 |
| VascepaIcosapent Ethyl | 29 | $17,573 |
| TrulicityDulaglutide | 11 | $16,162 |
| EntrestoSacubitril/Valsartan | 12 | $9,845 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $5,861 |
| Azathioprine | 13 | $4,923 |
| Ezetimibe | 73 | $4,190 |
| Atorvastatin Calcium | 347 | $4,184 |
| Rosuvastatin Calcium | 126 | $3,467 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $3,139 |
| Metoprolol Succinate | 156 | $2,888 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $413 | $112,675121 claims |
| Lilly USA, LLCMounjaro, Trulicity | $598 | $77,92974 claims |
| Boehringer IngelheimJardiance | $109 | $34,44928 claims |
| MerckJanumet Xr | $99 | $24,46021 claims |
| GSKTrelegy Ellipta | $147 | $23,97826 claims |
| AbbVieSynthroid | $23 | $49917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Newburyport
- David SchenkeinBoston$5M
- Alan GarberCambridge$4.9M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Sandra RichmanBrookline$1.4M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.